North East-made vaccine could be fourth to be approved for UK use as trial suggests it is 89% effective in preventing Covid

The country has secured 60 million doses of the Novavax jab – to be produced on Teesside – which is believed to offer protection against the new UK and South African variants.

It was shown to be 89.3% effective at preventing coronavirus in participants in its Phase 3 clinical trial in the UK.

That involved more than 15,000 people aged between 18-84, of which 27% were older than 65, Novavax said.

The vaccine will now be assessed by the Medicines and Healthcare products Regulatory Agency (MHRA), Prime Minister Boris Johnson confirmed, as he thanked volunteers who made the results possible.

Stan Erck, chief executive of Novavax, told the BBC the manufacturing plant in Stockton-on-Tees should be up and running by March or April, with the company hoping to get approval for the vaccine from the MHRA around the same time.

Health Secretary Matt Hancock said the NHS stands ready to roll out the vaccine if it is approved.

He said: “This is positive news and, if approved by the medicines regulator, the Novavax vaccine will be a significant boost to our vaccination programme and another weapon in our arsenal to beat this awful virus.”

Vaccines minister Nadhim Zahawi said he was “particularly thrilled to see such positive results” having taken part in the trial personally.

The chairman of the Government’s Vaccine Taskforce, Clive Dix, said the results were “spectacular”, adding: “The efficacy shown against the emerging variants is also extremely encouraging.

“This is an incredible achievement that will ensure we can protect individuals in the UK and the rest of the world from this virus.”

The jab has shown around 60% effectiveness against the South African variant, which has been worrying scientists due to concerns vaccines may not work against it, but it offered 86% protection against the new UK strain.

Two vaccines have already been rolled out in the UK – from Pfizer and Oxford/AstraZeneca – while a third from Moderna has been approved for use.

The Novavax jab would be delivered in the second half of 2021 if it receives MHRA approval.

You can subscribe to this website and enjoy unlimited access to local news, information and puzzles online.

With a digital subscription, you can read more than 5 articles, see fewer ads, enjoy faster load times, and get access to exclusive newsletters and content.

Simply click ‘Subscribe’ in the menu.